Risk factors for COVID-19 severity and mortality among inpatients in Southern Iran

FATEMEH REZAEI1, MOUSA GHELICHI-GHOJOGH2, ABDOLRASOOL HEMMATI3, HALEH GHAEM4, ALIREZA MIRAHMADIZADEH5
1 Department of Social Medicine, Jahrom University of Medical Sciences, Jahrom, Iran; 2 PhD Candidate in Epidemiology, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran; 3 Vice Chancellor Hemmati Affairs, Shiraz University of Medical Sciences, Shiraz, Iran; 4 Non-communicable Diseases Research Center, Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran; 5 Non-communicable Diseases Research Center, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran

Introduction

COVID-19 is a highly contagious respiratory disease and many factors can affect its severity and mortality. This study aimed to investigate the risk factors associated with the severity and mortality of COVID-19.

Methods

In this cross-sectional study, 311 cases with COVID-19 approved by the CORONALAB database in the Center for Disease Control and Prevention (CDC) in southern Iran were selected using systematic random sampling from 15 May to 13 June 2020. The data were collected through interviews and phone calls using a researcher-made questionnaire.

Results

The mean age of the participants was 45.82 ± 17.92 years, and the male to female ratio was 1.57:1. In addition, the Case Fatality Rate (CFR) was 4.50%, and the disease was severe in 47.5% of the cases. The most common clinical symptoms were cough (39.22%), fever (31.83%), and dyspnea (24.76%). The severity of COVID-19 was significantly associated with age and history of Cardiovascular Disease (CVD). Besides, the mortality of COVID-19 was significantly related to age, gender, hypertension, CVD, and Chronic Kidney Disease (CKD). The mean interval between the onset of the first symptom and referral to a health center was 3.02 ± 2.82 days. Additionally, the mean interval between the referral to health centers and testing was 0.88 ± 2.20 days.

Conclusion

Older patients, males, and those who had CVD, CKD, and hypertension required accurate healthcare and early intervention to prevent the exacerbation of COVID-19. Furthermore, the interval between the onset of the first symptom and testing was relatively long. Overall, early diagnosis, isolation, and treatment of patients were found to be essential to control COVID-19.
higher among the patients admitted to ICUs and severe cases compared to non-ICU and non-severe ones [14, 15]. Since the severity and mortality of COVID-19 disease can be affected by various factors, the present study aims to investigate the risk factors associated with the severity and mortality of COVID-19 with regard to the time interval between the onset of the first symptom and referring to health centers for testing.

Methods

STUDY DESIGN AND DATA COLLECTION
The Center for Disease Control and Prevention (CDC) for COVID-19 was established in Fars province on February 20, 2020 to monitor the spread of COVID-19. Fars province is the fourth most populous province in Iran, with Shiraz as its capital, that is located in south of the country. In this study, 311 COVID-19 cases approved by the CORONALAB database at the CDC of Shiraz University of Medical Sciences were selected using systematic random sampling from 15 May to 13 June 2020. Diagnosis of COVID-19 for the suspected cases was confirmed using throat and nose samples and Real-Time Polymerase Chain Reaction (RT-PCR) test. The data were collected using a researcher-made questionnaire. The reliability of the questionnaire was evaluated among 25 individuals via the test-retest method with a two-week interval. The intra-cluster correlation coefficient was 0.79, revealing the acceptable reliability of the questionnaire.

During active care, the patients received a phone call at home or were visited in the hospital. Then, their information was collected and completed via interviews. The history of diseases and medical records were checked for hospitalized patients. The patients who were isolated at home were called, as well. In case they mentioned the history of diseases, they were asked to refer to the health centers with their medical records for further examinations after the isolation period. The demographic characteristics of all the cases were recorded, which included age, gender, occupation, disease severity, patient care status, symptoms (fever, cough, shortness of breath, cyanosis, gastrointestinal problems, sore throat, and runny nose), comorbidities (diabetes, hypertension, cancer, CVD, and CKD), history of physical contact with patients, time of onset of the first symptom, and time of referring to health centers and testing. The patients were divided into severe and non-severe groups according to the severity of their disease and the American Thoracic Society guidelines for community-acquired pneumonia [16, 17].

STATISTICAL ANALYSIS
Relative and absolute frequencies were calculated for grouping the variables. Mean and standard deviation were calculated for quantitative variables. The relationships between the qualitative variables were determined by chi-square test. In addition, the interval between the onset of the first symptom and referral to health centers, the interval between referral to health centers and testing, and the interval between the onset of the first symptom and testing were calculated and their relationships with gender, disease severity, and mortality were assessed using t-test. The significance level was set at 0.05.

Results

The mean age of the cases was 45.82 ± 17.92 years. The youngest case was one year old and the oldest case was 87 years old. Most cases (49.02%) belonged to ≤ 45 age group. In addition, 61.09% of the cases were male, with the male to female ratio of 1.57:1.98. Besides, 39% of the cases were Iranian, and 9.65% were healthcare personnel. Moreover, 47.5% of the cases had severe disease and were admitted to the ICU. The most common clinical symptoms included cough (39.23%), fever (31.83%), and dyspnea (24.76%). The mortality rate was 4.50%. Furthermore, 15.76% of the patients had a history of physical contact with an infected person, 7.72% had diabetes, 6.75% had CVD, and 5.47% had hypertension.

The results showed a statistically significant relationship between the severity of COVID-19 and age (p = 0.017) and CVD (p = 0.021). There was also a statistically significant relationship between the mortality of COVID-19 and gender (p = 0.046), age (p = 0.001), hypertension (p = 0.034), CVD (p = 0.01), and CKD (p = 0.002). Cough was the prognostic factor for the severity of COVID-19, but had no significant relationship with mortality. The results also revealed no statistically significant relationship between nationality and occupation and COVID-19 severity and mortality (p > 0.05) (Tab. I).

The interval between the onset of the first symptom and referral to health centers and testing based on gender, disease severity, and mortality of COVID-19 has been presented in Table II. Accordingly, the mean interval between the onset of the first symptom and referral to health centers was 3.02 ± 2.82 days (range: 0-12 days), the mean interval between referral to health centers and testing was 0.88 ± 2.20 days (range: 0-12 days), and the mean interval between the onset of the first symptom and testing was 3.90 ± 3.55 days (range: 0-12 days). The results indicated a statistically significant relationship between the interval between the onset of the first symptom and testing and the mortality of COVID-19 (p < 0.001). The mean interval between the onset of the first symptom and testing was longer in the cases who were still alive than in the dead cases (3.99 ± 3.55 vs 0.63 ± 1.18).

Discussion

This study was conducted on 311 cases with COVID-19 approved by the CORONA database in southern Iran in order to determine the risk factors of COVID-19 severity and mortality. The results showed a statistically significant relationship between the severity of COVID-19 and age.
and CVD. In addition, the mortality of COVID-19 was significantly related to gender, age, hypertension, CVD, and CKD. The interval between the onset of symptoms and referral to health centers and testing was also assessed in the present study. The results demonstrated that COVID-19 mortality was significantly related to the interval between the onset of the first symptom and testing.

In the present study, the mean age of the cases was 45.82 ± 17.92 years. In another study, the mean age of the cases was 55.50 ± 15.15 years [18], which was higher

| Tab. I. Demographic and clinical characteristics of the COVID-19 cases. |
|---------------------------------------------------------------|
| **Variables** | **Disease severity** | **Disease mortality** | **P-value** |
| | Total n = 311 | Non-severe n = 294 | Severe n = 17 | Alive n = 297 | Dead n = 14 | **P-value** |
| **Gender** | | | | | | |
| Male | 190 (61.09) | 179 (94.21) | 11 (5.79) | 0.753 | 185 (97.37) | 5 (2.63) | 0.046 |
| Female | 121 (38.91) | 115 (95.04) | 6 (4.96) | 1.12 (92.56) | 9 (7.44) | 0.001 |
| **Age (years)** | | | | | | |
| < 25 | 26 (8.36) | 25 (96.15) | 1 (3.85) | 0.753 | 26 (100) | 0 (0) | 0.001 |
| 25-44 | 132 (42.44) | 130 (98.48) | 2 (1.52) | 0.017 | 132 (100) | 0 (0) | 0.001 |
| ≥ 45 | 153 (49.20) | 139 (90.85) | 14 (9.15) | 1 (9.15) | 153 (90.85) | 14 (9.15) | 0.001 |
| **Occupation** | | | | | | |
| Healthcare worker | 30 (9.65) | 30 (100) | 0 (0) | 0.388 | 29 (96.67) | 1 (3.33) | 1 |
| Non-healthcare worker | 281 (90.35) | 264 (93.95) | 17 (6.05) | 268 (95.37) | 13 (4.63) | 1 |
| **Nationality** | | | | | | |
| Iranian | 306 (98.39) | 289 (94.44) | 17 (5.56) | 1 | 292 (95.42) | 14 (4.58) | 1 |
| Non-Iranian | 5 (1.61) | 5 (100) | 0 (0) | 5 (100) | 0 (0) | 0.001 |
| **Signs and** symptoms | | | | | | |
| Cough | 122 (39.23) | 111 (90.98) | 11 (9.02) | 0.027 | 116 (95.08) | 6 (4.92) | 0.776 |
| Fever > 38 | 99 (31.83) | 95 (95.96) | 4 (4.04) | 0.450 | 96 (96.97) | 3 (5.03) | 0.560 |
| Sore throat | 61 (19.61) | 60 (98.36) | 1 (1.64) | 0.211 | 59 (96.72) | 2 (3.28) | 1 |
| Dyspnea | 77 (24.76) | 70 (90.91) | 7 (9.09) | 0.144 | 74 (96.10) | 3 (5.90) | 1 |
| Gastrointestinal problems | 37 (11.90) | 35 (94.59) | 2 (5.41) | 1 | 37 (90.70) | 3 (10.00) | 0.001 |
| Rhinorrhea | 18 (5.79) | 17 (94.44) | 1 (5.56) | 1 | 18 (99.00) | 1 (0.90) | 1 |
| Cyanosis | 4 (1.29) | 4 (100) | 0 (0) | 4 (100) | 0 (0) | 0.001 |
| Other | 7 (2.25) | 7 (100) | 0 (0) | 7 (100) | 0 (0) | 0.001 |
| History of contact with infected cases (yes) | 49 (15.76) | 48 (97.96) | 1 (2.04) | 0.684 | 48 (97.96) | 1 (2.04) | 0.293 |
| **Medical history** | | | | | | |
| Diabetes | 24 (7.72) | 22 (91.67) | 2 (8.33) | 0.630 | 21 (87.50) | 3 (12.50) | 0.084 |
| Hypertension | 17 (5.47) | 15 (88.24) | 2 (11.76) | 0.236 | 14 (82.35) | 3 (17.65) | 0.054 |
| Cardiovascular disease | 21 (6.75) | 17 (80.95) | 4 (19.05) | 0.021 | 17 (80.95) | 4 (19.05) | 0.010 |
| Chronic kidney disease | 7 (2.25) | 5 (71.43) | 2 (28.57) | 0.050 | 4 (57.14) | 3 (42.86) | 0.002 |
| Cancer | 3 (0.96) | 3 (100) | 0 (0) | 3 (100) | 0 (0) | 1 |
| Other diseases** | 12 (3.86) | 8 (66.67) | 4 (33.33) | 0.002 | 8 (66.67) | 4 (33.33) | 0.001 |
| | | | | | | |
| * Chi-square test; ** Other diseases included psychiatric diseases, cerebral palsy, rheumatoid arthritis, neurodegenerative diseases, stroke, etc. |

| Tab. II. The interval between the onset of the first symptom and testing for COVID-19 detection. |
|-----------------------------------------------|
| **Interval (day)** | **Gender** | **Disease severity** | **Disease mortality** |
| | Total | Male | Female | **P-value** | Non-severe | Severe | **P-value** | Alive | Dead | **P-value** |
| The first symptom to admission (µ ± SD) | 3.02 ± 2.82 | 2.99 ± 2.81 | 3.06 ± 2.83 | 0.845 | 3.03 ± 2.79 | 2.73 ± 3.52 | 0.726 | 3.02 ± 2.85 | 3 ± 2.20 | 0.984 |
| Admission to testing (µ ± SD) | 0.88 ± 2.20 | 0.87 ± 2.24 | 0.90 ± 2.21 | 0.923 | 0.90 ± 2.23 | 0.36 ± 1.21 | 0.429 | 0.84 ± 2.18 | 2.63 ± 2.44 | 0.078 |
| The first symptom to testing (µ ± SD) | 3.90 ± 3.55 | 3.88 ± 3.49 | 3.95 ± 3.65 | 0.897 | 3.93 ± 3.55 | 3.09 ± 3.65 | 0.443 | 3.99 ± 3.55 | 0.63 ± 1.18 | < 0.001 |
| * T-test. |
compared to the present study. In addition, the male to female ratio was 1.57:1, but this measure was found to be 1.93:1 and 1.6:1 in the studies conducted in Tehran and Shiraz, respectively [17, 18].

In the current investigation, 5.47% of the cases had the severe form of the disease. In another study, approximately 14% of the people infected with COVID-19 had severe disease and 6% had very severe disease [19]. In the current study, severe cases included those admitted to the ICU. Furthermore, 9.65% of the cases were healthcare personnel, while this measure was found to be 2.8% in another research [17].

The current study findings revealed that the Case Fatality Rate (CFR) was 4.50% in all the cases and 35.29% in severe ones. The results of a systematic review and meta-analysis indicated that CFR was 13% in hospitalized cases [6]. In other studies conducted in Iran, CFR was reported to be 8.06 and 55.6% in hospitalized patients [17, 18]. This measure was found to be 15 and 11% in China [7, 20]. Overall, the CFR was lower in the present study than in other studies, which might be due to the prompt and timely treatment of severe COVID-19 cases.

The present study findings revealed a significant relationship between age and COVID-19 severity and mortality. Accordingly, COVID-19 was more severe and resulted in higher mortality in older ages. Other studies have also shown a higher risk of mortality in older ages [18, 21]. The reasons for the higher severity and mortality of COVID-19 at older ages could be the higher prevalence of comorbidities in this age group. It has also been stated that old age was associated with the decreased immune system capacity [22].

The present study findings demonstrated a significant relationship between gender and COVID-19 mortality (p = 0.046). Based on the results, nearly 35% of the severe cases and 63% of the dead ones were female. However, other studies indicated that the mortality rate was higher in males than in females [17, 18, 23]. In a prior research, estrogen protected against such pathogens as HIV, hepatitis C virus, Ebola, and human cytomegalovirus in females [24]. Estrogen receptor signaling also played an essential role in coronavirus infection and mortality [25]. Another study demonstrated that estrogen signaling could be one of the reasons for the rapid recuperation and low mortality due to COVID-19 amongst females [26]. The discrepancy between the results might be associated with the comorbidities or higher age of the females suffering from COVID-19 in the present study.

The current study results showed that the severity of COVID-19 was significantly associated with CVD and its mortality was correlated to hypertension, CVD, and CKD. The results of a meta-analysis also revealed that the mortality of COVID-19 was higher in patients with CVD and CKD [27]. Countries with the highest mortality rates such as the United States, Europe, and China have been shown to have the highest incidence of these chronic diseases [28]. The results of another study proved that hypertension increased the risk of severity or mortality of COVID-19 by almost 2.5 times [29]. Moreover, the risk of developing severe COVID-19 was three times higher in the CKD patients than in those without CKD. The suppressed immune system might significantly predispose CKD patients to infectious complications. Likewise, having a chronic systemic inflammation could increase their mortality [30]. In addition to the explored variables, a high genetic burden was strongly related to the severity and hospitalization risk of COVID-19, particularly amongst people with few recognized risk factors [31].

In the present study, cough (39.23%) was the most common clinical symptom as well as a prognostic factor for the disease severity (p = 0.027). Similarly, other studies indicated that cough was a common clinical symptom of COVID-19 [32, 33]. Another research also revealed that cough was associated with the severity of COVID-19 [32, 34], which was in agreement with the current study findings [8, 33]. The results of the present investigation showed that the mean interval between the onset of the first symptom and referral to health centers was 3.02 ± 2.82 days, the mean interval between referral to the health centers and testing was 0.88 ± 2.20 days, and the mean interval between the onset of the first symptom and testing was 3.90 ± 3.55 days. There was a statistically significant relationship between the interval between the onset of the first symptom and testing and the mortality of COVID-19 (p < 0.001). Accordingly, the mean interval between the onset of the first symptom and testing was longer in the alive cases than in the dead ones (3.99 ± 3.55 vs 0.63 ± 1.18 days). In fact, the patients who died had more severe symptoms at the onset of the disease and, consequently, they had referred to health centers for treatment earlier, while it took longer to take the test from the patients who did not have severe symptoms. Since the people who are asymptomatic or have mild symptoms are still able to transmit the disease, it is necessary to examine all the patients immediately after their referral to health centers. Due to the fact that the mean interval between the onset of the first symptom and referral to health centers and testing was relatively long, there is a need for public education and raising public awareness about the symptoms of COVID-19 and referral to health centers for testing as soon as possible.

One of the strong points of the present research was that it evaluated the relationship between the severity and mortality of COVID-19 and the interval between the onset of the first symptom and referral to health centers, interval between referral to health centers and testing, and interval between the onset of the first symptom and testing. However, one of the limitations of the study was that the patients’ biochemical test results and lung CT scans were not available. Therefore, further studies are required to consider other risk factors such as laboratory and radiological markers in addition to demographic and clinical factors. Moreover, the researchers did not have access to the patients’ complete information about the history of diseases such as diabetes (HbA1c, controlled or not), cancer status (current or past, type of cancer, stage, and course of therapy), and CKD stages. Another study limitation was related to the interview method. In fact, the history of diseases and medical records were checked for the hospitalized patients, while phone calls
were made to contact the patients who were isolated at home. In case they mentioned the history of diseases, they were asked to refer to the health centers with their medical records for further examinations.

Conclusions

Old age and CVD were associated with the severity of the disease in patients with COVID-19. Therefore, these patients required accurate healthcare as well as early intervention to prevent the exacerbation of the disease. Moreover, older age, female gender, and having a history of hypertension, CVD, and CKD might increase the risk of COVID-19 mortality. Since the interval between the onset of the first symptom and testing was relatively long, it is essential to make a timely diagnosis, stay in quarantine, and treat the patients as soon as possible to control COVID-19. Future studies are suggested to evaluate the predictors of COVID-19 severity and mortality based on the risk factors revealed in the present research.

Acknowledgements

Funding sources: this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The Research Ethics Committee of Shiraz University of Medical Sciences (IR.SUMS.REC.1399.803) approved this study. The authors would like to express their deepest gratitude to all healthcare personnel at Shiraz University of Medical Sciences and special thanks to the staff of the Center for Disease Prevention and Control. They would also like to appreciate Ms. A. Keivanshekouh at the Research Consultation Center (RCC) of Shiraz University of Medical Sciences for improving the use of English in the manuscript.

Conflict of interest statement

The authors declare no conflict of interest.

Authors’ contributions

All authors contributed to the study conception and design. AMA and HG participated in the design of the study. MGG and FR performed data collection, wrote the manuscript, helped with statistical analysis, and prepared the illustrations. AH and FR edited the manuscript. All authors read and approved the final manuscript.

References

[1] WHO. Coronavirus Disease 2019 (COVID-19) Outbreak. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (Accessed on: 18 February 2020).
[2] Chen L, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020;20:398-400. https://doi.org/10.1016/S1473-3099(20)30141-9
[3] Lipstitch M, Finelli L. Defining the epidemiology of Covid-19 - Studies needed. N Engl J Med 2020;382:1194-6. https://doi.org/10.1056/NEJMhp2002125
[4] Wang C, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020;395:470-3. https://doi.org/10.1016/S0140-6736(20)30185-9. Erratum in: Lancet 2020 Jan 29.
[5] Alimohamadi Y, Sepandi M. Estimate of the basic reproduction number for COVID-19: a systematic review and meta-analysis. J Prev Med Public Health 2020;53:151-7. https://doi.org/10.3961/jpmph.20.076
[6] Rodriguez-Morales AJ, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, Alvarado-Arnez LE, Bonilla-Aldana DK, Franco-Paredes C, Henao-Martínez AF, Paniz-Mondolfi A, Lagos-Grisesales GJ, Ramírez-Vallejo E, Suárez JA, Zambrano LI, Villamil-Gómez WE, Balbin-Ramon GJ, Rabaan AA, Harapan H, Dhama K, Nishiura H, Kataoka H, Ahmad T, Sah R; Latin American Network of Coronavirus Disease 2019-COV- ID-19 Research (LANCOVID-19). Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis 2020;34:101623. https://doi.org/10.1016/j.tmaid.2020.101623
[7] Chen N, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-513. https://doi.org/10.1016/S0140-6736(20)30211-7
[8] Zhou F, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62. https://doi.org/10.1016/S0140-6736(20)30566-3. Erratum in: Lancet 2020;395:1038.
[9] To KK, Oyanagi T, Yap C, Chan KH, Wu TC, Chan JM, Leung WS, Huang Y, Yip CC, Chan KH, Wu TC, Chan JM, Leung WS, Ng SI, Mak KH, Kwong YL, Li D, Wu PW, Liu J, Tse WC, Poon LM, Yuen KY. Consistent Detection of 2019 Novel Coronavirus in Saliva. Clin Infect Dis. 2020 Jul 28;71(15):841-843. https://doi.org/10.1093/cid/ciaa149. PMID: 32047895.
[10] Hui DS, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C, Zambon M, Aerts M, Ammar W, Beutels P, Bouadma L, Boukhris O, Cauda R, Domingo P, Gubareff M, Hui WM, Jafari K, Kim SK, Kuchenbaecker JA, Ksiazek TG, Legendre N, Li LM, Ling LF, Liu H, Lopez G, Marjani SL, Moreira AL, Morocho T, Niedrig M, Osterholm MT, Pipas JM, Remenik D, Rimland D, Rota PG, Salgado RF, Salgado E, van Boeijen A, Varela M, Vene A, Wang W, Wang Z, Wang ZJ, Wang Y, Xu H, Yang R, Yu J, Zhang L, Zhang LL, Zhou W, Zomke J, Zou L, Zou L, Zou X. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020;91:264-6. https://doi.org/10.1016/j.ijid.2020.01.009
[11] Yu C, Li W, Wang X, Liu W, Fan X, Li W. Clinical characteristics, associated factors, and predicting COVID-19 mortality risk: a retrospective study in Wuhan, China. Am J Prev Med 2020;59:168-75. https://doi.org/10.1016/j.amepre.2020.05.002
[12] Cen Y, Zou Y, Zhang XH, Cheng X, Xu C, Jiang WR, Xu HT, Chen Y, Zhu J, Zhang LL, Liu YH. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multicentre observational study. Clin Microbiol Infect 2020;26:1242-7. https://doi.org/10.1016/j.cmi.2020.05.041
[13] Ozyelde T, Canciani G. Prognosis of COVID-19 in patients with liver and kidney diseases: an early systematic review and meta-analysis. Trop Med Infect Dis 2020;5:80. https://doi.org/10.3390/td.202005020080
[14] Grasselli G, Zanella A, Albano G, Antonelli M, Bellani G, Bonanomi E, Cabrini L, Carlesso E, Castelli G, Cattaneo S, Cereda D, Cobolombo S, Colocullo A, Crescini G, Forastieri Molinari A, Foti G, Fumagalli R, Iotti GA, Langer T, Latorcio N, Lorini FL, Mogli F, Natalini G, Pessina CM, Ranieri VM, Rech R, Scudeller L, Rosano A, Storti E, Thompson BT, Tirani M, Villani PG, Pesenti A, Cecconi M; COVID-19 Lombardy ICU Network. Risk factors associated with mortality among patients with COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med 2020;180:1345-
RISK FACTORS FOR COVID-19 SEVERITY AND MORTALITY

Guan WJ, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei WX, Wu C, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Zhao S, Ran J, Musa SS, Yang G, Wang W, Lou Y, Gao D, Yang RL. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet 2020;395:931-4. https://doi.org/10.1016/S0140-6736(20)30567-5

Huang C, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus disease (COVID-19) in the South of Iran. BMC Infect Dis 2020;20:427. https://doi.org/10.1186/s12879-020-05126-x

Nikpouraghdam M, Alishiri G, Heydari S, Ebrahimnia M, Samadinia H, Sepandi M, Safari N, Izadi M, Qazvini A, Dorostkar R, Tat M, Shahriri I, Afnan G, Hosseini Zijoud SR, Taghdir M, Alimohamadi Y, Abbaspasand S, Gouvarchin Ghalheh HE, Bagheri M. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in Iran: a single center study. J Clin Virol 2020;127:104378. https://doi.org/10.1016/j.jcv.2020.104378

Anderson RM, Klinkenberg D, Hollingsworth TD. What will the impact of (COVID-19) be on the population? J R Soc Med 2020;113:551-2. https://doi.org/10.1177/0950268820935955. Erratum in: J R Soc Med 2020;113:551-2.

Li K, Wu F, Guo D, Chen L, Fang Z, Li C. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Invest Radiol 2020;55:327-31. https://doi.org/10.1097/RLI.0000000000000672

Received on April 4, 2021. Accepted on October 28, 2021.

Correspondence: Alireza Mirahmadizadeh, Non-communicable Diseases Research Center, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran - Tel.: (98) 711 7251001 - Fax: (98) 711 7260225 - E-mail: mirahmadia@sums.ac.ir

How to cite this article: Rezaei F, Ghelichi-Ghojogh M, Hemmati A, Ghаем H, Mirahmadizadeh A. Risk factors for COVID-19 severity and mortality among inpatients in Southern Iran. J Prev Med Hyg 2021;62:E808-E813. https://doi.org/10.15167/2421-4248/jpmh2021.62.4.2130

© Copyright by Pacini Editore Sd, Pisa, Italy

This is an open access article distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license. The article can be used by giving appropriate credit and mentioning the license, but only for non-commercial purposes and only in the original version. For further information: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en